Orchestra BioMed (OBIO) News Today $4.72 -0.48 (-9.23%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$4.74 +0.02 (+0.32%) As of 02/21/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Orchestra BioMed to Present at Upcoming Investor ConferencesFebruary 20 at 8:00 AM | globenewswire.comOrchestra names Vivek Reddy as chairman of BACKBEAT study steering committeeFebruary 19 at 12:59 AM | markets.businessinsider.comOrchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory BoardFebruary 18, 2025 | globenewswire.comBarclays Reaffirms Their Buy Rating on Orchestra BioMed Holdings (OBIO)February 15, 2025 | markets.businessinsider.comOrchestra BioMed (NASDAQ:OBIO) Trading 5.1% Higher - Here's WhyOrchestra BioMed (NASDAQ:OBIO) Trading Up 5.1% - What's Next?February 14, 2025 | marketbeat.comOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Sees Large Decline in Short InterestOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 474,000 shares, a decline of 35.7% from the January 15th total of 736,700 shares. Based on an average daily volume of 97,000 shares, the short-interest ratio is presently 4.9 days. Approximately 1.8% of the company's shares are short sold.February 14, 2025 | marketbeat.comOrchestra BioMed announces data on atrioventricular interval modulation therapyFebruary 12, 2025 | markets.businessinsider.comOrchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 ConferenceFebruary 12, 2025 | globenewswire.comOrchestra BioMed announces appointment of Cleary to board of directorsFebruary 6, 2025 | markets.businessinsider.comOrchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of DirectorsFebruary 5, 2025 | globenewswire.comOrchestra BioMed Hldgs (NASDAQ:OBIO) Stock Quotes, Forecast and News SummaryJanuary 3, 2025 | benzinga.comBarclays Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Overweight RecommendationJanuary 3, 2025 | msn.comOrchestra BioMed Up 49% After Barclays Starts Coverage With $16 TargetJanuary 2, 2025 | marketwatch.comOrchestra BioMed initiated with an Overweight at BarclaysJanuary 2, 2025 | markets.businessinsider.comOrchestra BioMed (NASDAQ:OBIO) Now Covered by BarclaysBarclays assumed coverage on shares of Orchestra BioMed in a research report on Thursday. They issued an "overweight" rating and a $16.00 target price on the stock.January 2, 2025 | marketbeat.comInsider Buying: Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Insider Acquires 4,000 Shares of StockDecember 27, 2024 | insidertrades.comInsider Buying: Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Insider Purchases 4,000 Shares of StockOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) insider David P. Hochman purchased 4,000 shares of the stock in a transaction dated Monday, December 23rd. The shares were bought at an average price of $4.66 per share, with a total value of $18,640.00. Following the completion of the acquisition, the insider now directly owns 579,498 shares of the company's stock, valued at approximately $2,700,460.68. This represents a 0.70 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.December 26, 2024 | marketbeat.comOrchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) top owners are individual investors with 26% stake, while 22% is held by hedge fundsDecember 25, 2024 | uk.finance.yahoo.comOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Insider David P. Hochman Acquires 5,000 SharesDecember 20, 2024 | insidertrades.comInsider Buying: Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Insider Buys 5,000 Shares of StockOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) insider David P. Hochman acquired 5,000 shares of the company's stock in a transaction dated Wednesday, December 18th. The shares were bought at an average cost of $4.91 per share, with a total value of $24,550.00. Following the purchase, the insider now owns 575,498 shares in the company, valued at approximately $2,825,695.18. The trade was a 0.88 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.December 19, 2024 | marketbeat.comOrchestra BioMed Announces AVIM Therapy Program Presentations at ICI MeetingDecember 10, 2024 | markets.businessinsider.comRTW Investments LP Purchases 2,585,519 Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO)RTW Investments LP grew its position in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) by 46.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,206,159 shares of the company's stock afDecember 5, 2024 | marketbeat.comOrchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | globenewswire.comFY2024 EPS Estimates for Orchestra BioMed Raised by B. RileyOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Stock analysts at B. Riley upped their FY2024 EPS estimates for Orchestra BioMed in a research note issued on Wednesday, November 13th. B. Riley analyst K. Bauser now forecasts that the company will post earnings of ($1.67) per share fNovember 18, 2024 | marketbeat.comResearch Analysts Offer Predictions for OBIO FY2024 EarningsOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Equities researchers at Chardan Capital dropped their FY2024 EPS estimates for shares of Orchestra BioMed in a note issued to investors on Wednesday, November 13th. Chardan Capital analyst K. Nakae now expects that the company will posNovember 18, 2024 | marketbeat.comHC Wainwright Has Optimistic Outlook of OBIO FY2024 EarningsOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Research analysts at HC Wainwright upped their FY2024 earnings estimates for shares of Orchestra BioMed in a report issued on Thursday, November 14th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings peNovember 18, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Orchestra BioMed (NASDAQ:OBIO)HC Wainwright restated a "buy" rating and set a $14.00 price objective on shares of Orchestra BioMed in a research note on Friday.November 15, 2024 | marketbeat.comOrchestra BioMed’s Strong Financial Performance and Strategic Developments Reinforce Buy Rating with $14 Price TargetNovember 15, 2024 | markets.businessinsider.comOrchestra BioMed Holdings: Strategic Financial Developments and Clinical Progress Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comOrchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business UpdateNovember 12, 2024 | globenewswire.comOrchestra BioMed to Present at Jefferies London Healthcare ConferenceNovember 9, 2024 | msn.comOrchestra BioMed Holdings IncNovember 8, 2024 | morningstar.comOrchestra BioMed to Participate in Jefferies London Healthcare ConferenceNovember 7, 2024 | markets.businessinsider.comDavid P. Hochman Purchases 2,500 Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) StockSeptember 27, 2024 | insidertrades.comOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Director Sells $11,280.00 in StockSeptember 11, 2024 | insidertrades.comOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Director Eric S. Fain Sells 2,000 Shares of StockOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) Director Eric S. Fain sold 2,000 shares of the company's stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $5.64, for a total transaction of $11,280.00. Following the completion of the sale, the director now owns 44,810 shares in the company, valued at approximately $252,728.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.September 10, 2024 | marketbeat.comInsider Selling: Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Insider Sells 6,819 Shares of StockSeptember 7, 2024 | insidertrades.comOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Insider Darren Sherman Sells 6,837 SharesSeptember 7, 2024 | insidertrades.comHC Wainwright & Co. Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Buy RecommendationAugust 23, 2024 | msn.comHC Wainwright Begins Coverage on Orchestra BioMed (NASDAQ:OBIO)HC Wainwright started coverage on Orchestra BioMed in a report on Thursday. They issued a "buy" rating and a $14.00 price target for the company.August 22, 2024 | marketbeat.comFY2024 EPS Estimates for Orchestra BioMed Holdings, Inc. Lowered by Analyst (NASDAQ:OBIO)Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Investment analysts at Chardan Capital lowered their FY2024 EPS estimates for Orchestra BioMed in a research note issued on Tuesday, August 13th. Chardan Capital analyst K. Nakae now expects that the company will post earnings of ($1.6August 16, 2024 | marketbeat.comOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Insider Purchases $14,600.00 in StockAugust 16, 2024 | insidertrades.comInsider Buying: Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Insider Buys 2,500 Shares of StockOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) insider David P. Hochman bought 2,500 shares of Orchestra BioMed stock in a transaction that occurred on Wednesday, August 14th. The stock was bought at an average price of $5.84 per share, for a total transaction of $14,600.00. Following the completion of the acquisition, the insider now directly owns 567,998 shares of the company's stock, valued at $3,317,108.32. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.August 15, 2024 | marketbeat.comMDT Aug 2024 81.000 putAugust 15, 2024 | uk.finance.yahoo.comOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Forecasted to Earn Q3 2024 Earnings of ($0.43) Per ShareOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - B. Riley dropped their Q3 2024 EPS estimates for Orchestra BioMed in a report released on Tuesday, August 13th. B. Riley analyst K. Bauser now forecasts that the company will post earnings of ($0.43) per share for the quarter, down froAugust 15, 2024 | marketbeat.comMDT Aug 2024 87.000 callAugust 15, 2024 | uk.finance.yahoo.comOrchestra BioMed Holdings Reports Second Quarter 2024 Financial Results and Business UpdatesAugust 15, 2024 | msn.comOrchestra BioMed (NASDAQ:OBIO) Issues Earnings ResultsOrchestra BioMed (NASDAQ:OBIO - Get Free Report) released its earnings results on Monday. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.04). Orchestra BioMed had a negative net margin of 2,330.46% and a negative return on equity of 70.18%. The business had revenue of $0.78 million for the quarter, compared to the consensus estimate of $1.04 million.August 14, 2024 | marketbeat.comOrchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business UpdateAugust 14, 2024 | finanznachrichten.deBuy Rating Affirmed for Orchestra BioMed on Strong Financials and Promising BackBeat CNT DevelopmentsAugust 14, 2024 | markets.businessinsider.com Get Orchestra BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address OBIO Media Mentions By Week OBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OBIO News Sentiment▼0.310.60▲Average Medical News Sentiment OBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OBIO Articles This Week▼41▲OBIO Articles Average Week Get Orchestra BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BVS News Today AXGN News Today CBLL News Today AVNS News Today IRMD News Today SIBN News Today TMCI News Today KIDS News Today DCTH News Today CLPT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OBIO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchestra BioMed Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orchestra BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
